Synthetic cocoa chemical slows growth of tumors in human cell lines

A synthetic chemical based on a compound found in cocoa beans slowed growth and accelerated destruction of human tumors in laboratory studies, and should be tested further for cancer chemoprevention or even treatment, say researchers at Georgetown University Medical Center.

"We have all heard that eating chocolate is good for you; this study suggests one reason why that might be true," says the study's lead author Min Kim, Ph.D., a research scientist in the Department of Oncology at Lombardi Comprehensive Cancer Center.

Published online today in Cell Cycle, the researchers describe how four different human tumor cells lines out of 16 tested were sensitive to the chemical, known as GECGC. The strongest response was seen in two different colon cancers; growth was cut in half and most of the tumor cells were damaged.

Normal cells were not affected by GECGC, which makes the chemical a candidate for cancer chemoprevention, says Kim.

"This chemical seems to be safe, which makes sense because it has a structure similar to a natural product in cocoa beans - the same beans that are used to make chocolate," he says.

The researchers have long studied the beneficial effects of flavanols, which are molecules in vegetables and fruits that exhibit potent anti-oxidant and, potentially, anti-tumor properties. As part of these studies, investigators have been testing a new synthetic version of natural procyanidins, a class of flavanols, created and patented by the confectionery company, Mars Incorporated. (The company provided GECGC as a gift, and this project was funded in part by Mars Incorporated.)

In these studies, the scientists tested the effects of three different doses of GECGC on the cancer cell lines - the first time that a synthetic cocoa derivative has been used to screen human cancer cell lines. None of the doses tested were extreme, Kim points out. "The effective concentrations were considered similar to what a person might eat or use," he says.

They found sensitivity to GECGC in both colon cancer cell lines they tested, in cervical cancer cells and in one line of leukemia, tumor cells. Other cell lines were resistant, including ovarian and prostate cancer cells.

Overall, GECGC showed the most effect in treating cancer cells that are normally fast growing, Kim says. And the fact that it demonstrated the most killing power in colon cancer suggests the chemical "could serve as a promising therapeutic for colon cancer," he says. "So far, these data are very convincing."

The researchers do not yet clearly understand the mechanism by which GECGC disrupts tumor growth, but they think it inhibits the physical connections between cancer cells and blocks internal cell signaling pathways.

Kim says that animal studies testing the anticancer power of GECGC are currently underway. "While this work is indeed promising, we have much more study to do before we can say with authority that GECGC has anticancer properties."

Source: Georgetown University

Related stories:

Researchers devise means to create blood by identifying earliest stem cells
Johns Hopkins researchers have discovered the earliest form of human blood stem cells and deciphered the mechanism by which these embryonic stem cells replicate and grow. They also found a surprising biological marker that pinpoints these stem cells, which serve as the progenitors for red blood cells and lymphocytes.
World first: Lasers used in keyhole surgery for brain cancer
In a ground-breaking advance, French neurosurgeons on Friday said they had successfully treated brain tumours through ultra-keyhole surgery, using a tiny fibre-optic laser to destroy cancerous cells.
Growth factor predicts poor outcome in breast cancer
The response to insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts an aggressive tumor that is less likely to respond to treatment, said researchers at Baylor College of Medicine in a report that appears in the current issue of the Journal of Clinical Oncology. The finding gives impetus to the movement to tailor cancer treatments to attributes of the various tumors.
Location, location, location important for genes, too
Cells become cancerous mainly because they lose control of their growth. To better understand how this happens, a new study at Ohio State University's Comprehensive Cancer Center looks at four genes that help regulate cell growth in embryos and that contribute to cancer in adults.
Scientists discover new link in pathway to cancer: hope for drug design
(PhysOrg.com) -- University of Manchester scientists have identified an exciting connection between a cell’s extracellular environment and the activity of a signalling pathway molecule that controls the development of organs and tissues, as well as cancer and kidney disease.
Variation of normal protein could be key to resistance to common cancer drug
Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.
New role for natural killers
Scientists at the University of York have discovered a new role for a population of white blood cells, which may lead to improved treatments for chronic infections and cancer.
Gene that causes childhood cancer neuroblastoma is found
Scientists have discovered gene mutations that are the main cause of the inherited version of the childhood cancer neuroblastoma. In addition, the researchers found that the same mutations play a significant role in high-risk forms of non-inherited neuroblastoma, the more common form of the disease.

News discussion:

Medicine & Health news